Phase I?II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer
- 1 January 1995
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 36 (3) , 259-262
- https://doi.org/10.1007/bf00685857
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Octreotide and Bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with flutamide and castrationEuropean Journal of Cancer and Clinical Oncology, 1990
- Somatostatin and somatostatin analogues in oncologyCancer Treatment Reviews, 1989
- Immunoreactive Somatostatin in Male Reproductive System in Humans*Journal of Clinical Endocrinology & Metabolism, 1989
- Potential role of somatostatin analogues in the treatment of cancerEuropean Journal of Clinical Investigation, 1987
- Pharmacological studies of somatostatin and somatostatin-analogues: Therapeutic advances and perspectivesLife Sciences, 1987
- Autocrine growth factors and cancerNature, 1985
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Prostatic CarcinomaNew England Journal of Medicine, 1979
- Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth HormoneScience, 1973